Aim: Several ocular and systemic complications have been reported after the bevacizumab intravitreal injection. This study aims at reporting the main indications for the bevacizumab intravitreal injection in our center, the intravitreal injection method in this study, and the incidence of the post-injection complication, such as endophthalmitis.Methods: This study is a retrospective review of t...

Aflibercept (Eylea) injection (CPB 0701 Vascular Endothelial Growth Factor Inhibitors for Ocular Indications) Bevacizumab (Avastin) injection (CPB 0685 Bevacizumab (Avastin)) Pegaptanib sodium (Macugen) injection (CPB 0701 Vascular Endothelial Growth Factor Inhibitors for Ocular Indications) Photodynamic therapy (PDT) with light-activated verteporfin (CPB 0594 Visudyne (Verteporfin) Photodynami...

We report a 64-year-old diabetic woman who developed neovascularization of the posterior capsule 2 years after cataract surgery and intraocular lens implantation. The patient was treated with single injection of 1.25 mg of intravitreal bevacizumab (Avastin) via pars plana. After one week, complete regression of the posterior capsule neovascularization was achieved allowing us to perform Nd: YAG...

to evaluate corneal endothelial cell changes after intravitreal and subconjunctival injection of avastin (bevacizumab) based on specular microscopic findings.  this prospective interventional study was performed on 82 eyes of 82 patients. forty-two cases with ptrygia received a subconjunctival injection of bevacizumab (2.5mg/0.2ml) and 40 diabetic subjects with retinal neovascularization or mac...

we report a 64-year-old diabetic woman who developed neovascularization of the posterior capsule 2 years after cataract surgery and intraocular lens implantation. the patient was treated with single injection of 1.25 mg of intravitreal bevacizumab (avastin) via pars plana. after one week, complete regression of the posterior capsule neovascularization was achieved allowing us to perform nd: yag...

We developed a point-of-care testing method based on lateral flow assay for bevacizumab, using an anti-idiotypic DNA aptamer as the capture molecule. Bevacizumab loaded onto sample pad strip bound to red-colored aptamer-modified gold nanoparticles (AuNPs) in conjugation and then migrated into developing zone. The AuNPs bevacizumab were trapped by protein A test spot. In contrast, excess amounts...

normal 0 false false false en-us x-none ar-sa microsoftinternetexplorer4 background : diabetic macular edema (dme) is the most common cause of reduced vision in diabetic patients. with regards to its prevalence and its severe morbidity, attention to new methods of treatment like anti-vascular endothelial growth factor (vegf) therapy is of great importance. therefore, this study aimed to evaluat...

800x600 to report the efficacy of combination therapy (bevacizumab and photocoagulation) in a case of eales disease this study has been performed. bevacizumab (avastin, 1.25 mg/0.05 ml) was injected intravitreously for the treatment of iris and retinal neovascularization in a 56-year old hispanic female with photocoagulation treatment to control the recurrence of vitreous haemorrhage. our resul...